Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced the enrollment of the first patient in a Phase II clinical study for its investigational drug M701. M701 is a recombinant anti-EpCAM and CD3 human murine chimeric bispecific antibody (BsAb) injection, currently under assessment as a potential treatment for malignant pleural effusion.
The Phase II study aims to evaluate the efficacy and safety of thoracic infusion of M701. It will be compared against thoracic puncture drainage and/or thoracic chemotherapy in patients with malignant pleural effusion resulting from non-small cell lung cancer (NSCLC). EpCAM serves as a tumor cell target, while CD3 is an immune T cell activation target. M701 is designed to activate immune cells and simultaneously inhibit tumor cell growth within the chest cavity, thus inhibiting the development of pleural effusion. A previous Phase Ib study had yielded promising safety and efficacy data for this drug candidate.- Flcube.com
